147 related articles for article (PubMed ID: 38718066)
1. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
[TBL] [Abstract][Full Text] [Related]
2. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
PeerJ; 2022; 10():e14193. PubMed ID: 36248712
[TBL] [Abstract][Full Text] [Related]
3. Quantitative detection and prognostic value of antibodies against M-type phospholipase A2 receptor and its cysteine-rich ricin domain and C-type lectin domains 1 and 6-7-8 in patients with idiopathic membranous nephropathy.
Liu X; Xue J; Li T; Wu Q; Sheng H; Yang X; Lin B; Zhou X; Qin Y; Huang Z; Zhou L; Wang L; Hu Z; Huang B
PLoS One; 2024; 19(2):e0298269. PubMed ID: 38386672
[TBL] [Abstract][Full Text] [Related]
4. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
Li C; Li H; Wen YB; Li XM; Li XW
BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
[TBL] [Abstract][Full Text] [Related]
5. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome.
Duan S; Chen S; Chen C; Lu F; Pan Y; Lu Y; Li Q; Liu S; Zhang B; Mao H; Xing C; Yuan Y
Ren Fail; 2024 Dec; 46(1):2359024. PubMed ID: 38832491
[TBL] [Abstract][Full Text] [Related]
7. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
8. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
[TBL] [Abstract][Full Text] [Related]
9. Quantitative detection of anti-PLA2R antibodies targeting different epitopes and its clinical application in primary membranous nephropathy.
Qin Y; Wu Q; Sheng H; Li T; Liu X; Yang X; Lin B; Zhou X; Jin J; Wang L; Huang B; He Q; Hu Z
Clin Chem Lab Med; 2023 Jan; 61(2):251-259. PubMed ID: 36351699
[TBL] [Abstract][Full Text] [Related]
10. Primary Membranous Nephropathy.
Couser WG
Clin J Am Soc Nephrol; 2017 Jun; 12(6):983-997. PubMed ID: 28550082
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
[No Abstract] [Full Text] [Related]
12. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
[TBL] [Abstract][Full Text] [Related]
13. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
14. Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy.
Quintana LF; Blasco M; Seras M; Pérez NS; López-Hoyos M; Villarroel P; Rodrigo E; Viñas O; Ercilla G; Diekmann F; Gómez-Roman JJ; Fernandez-Fresnedo G; Oppenheimer F; Arias M; Campistol JM
Transplantation; 2015 Aug; 99(8):1709-14. PubMed ID: 25675198
[TBL] [Abstract][Full Text] [Related]
15. Structural determinants of the dominant conformational epitopes of phospholipase A2 receptor in primary membranous nephropathy.
Tang H; Zhu R; Waldman M; Zhu Q
J Biol Chem; 2022 Mar; 298(3):101605. PubMed ID: 35065076
[TBL] [Abstract][Full Text] [Related]
16. PLA2R antibody, PLA2R rs4664308 polymorphism and PLA2R mRNA levels in Tunisian patients with primary membranous nephritis.
Dhaouadi T; Abdellatif J; Trabelsi R; Gaied H; Chamkhi S; Sfar I; Goucha R; Ben Hamida F; Ben Abdallah T; Gorgi Y
PLoS One; 2020; 15(10):e0240025. PubMed ID: 33002091
[TBL] [Abstract][Full Text] [Related]
17. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Glomerular IgG Subclasses Switch in Idiopathic Membranous Nephropathy Classified by Glomerular Phospholipase A2 Receptor Antigen and Serum Antibody.
Cui HY; Li C; Li H; Wen YB; Duan L; Li Y; Yan XW; Hu YT; Chen LM; Li XM
Dis Markers; 2021; 2021():9965343. PubMed ID: 34497677
[TBL] [Abstract][Full Text] [Related]
20. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
